Polar Asset Management Partners’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Polar Asset Management Partners’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-15,000	Closed	-$576K	–	1069
2023 Q2	$576K	Sell	15,000 -134,600	-90%	-$3.46M	0.01%	549
2023 Q1	$3.46M	Hold	149,600	–	–	0.05%	418
2022 Q4	$3.92M	Hold	149,600	–	–	0.05%	492
2022 Q3	$2.94M	Sell	149,600 -167,011	-53%	-$3.35M	0.04%	636
2022 Q2	$5.54M	Buy	316,611 +134,311	+74%	+$2.11M	0.06%	438
2022 Q1	$2.98M	Hold	182,300	–	–	0.03%	550
2021 Q4	$2.97M	Buy	+182,300	New	+$2.59M	0.03%	537

Polar Asset Management Partners's KDNY Position: Q3 2023 in Review

Polar Asset Management Partners sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 15,000 shares — an estimated $576K sold.

Polar Asset Management Partners first reported a position in KDNY in Q4 2021 and held it in 7 quarters. The position peaked at $5.54M in Q2 2022. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Polar Asset Management Partners reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Polar Asset Management Partners sold 15,000 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $576K.
Polar Asset Management Partners first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Polar Asset Management Partners's Chinook Therapeutics, Inc. Common Stock position peaked at $5.54M in Q2 2022.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Polar Asset Management Partners's 13F filing for Q3 2023, filed 14 Nov 2023.